PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2117023
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 2117023
Targeted Radiopharmaceutical Market size was valued at US$ 5,108.7 Million in 2025, expanding at a CAGR of 10.9% from 2026 to 2033.
Targeted radiopharmaceuticals represent a special category of precision medicines that involve attaching a radioactive isotope to molecules that specifically target certain tissues. The targeted radiopharmaceuticals market consists of diagnostic PET and SPECT agents, therapeutic radioligands, radionuclide precursors, generators, radiolabeling equipment, and contract manufacturing and control services. The main area of application is oncology, primarily prostate cancer and neuroendocrine tumors, but there are also significant applications in cardiology and neurology. At the same time, the short half-lives of many isotopes mean that their production, sterile storage, transportation, and medical equipment are important aspects of the supply chain. In 2025, U.S. hospitals used approximately 40,000 doses of the isotope Mo-99 every day in diagnostic procedures. Therefore, the availability of isotopes plays an essential role in targeted radiopharmaceuticals, complementing the need to develop new molecules and cell targets, and is a major competitive advantage.
Targeted Radiopharmaceutical Market- Market Dynamics
Theranostics Is Reshaping Precision Treatment Pathways
The combination of molecular imaging and targeted therapy is leading to a more integrated approach to precision oncology. Theranostic platforms are designed to utilize diagnostic imaging to identify patients with tumor expression of a given target and then treat those patients with a theranostic agent that specifically targets the same receptor. As such, the development of these approaches is driving need for companion diagnostics, isotope supply chains, radiochemistry infrastructure, dosimetry, and specialized treatment centers. In March 2025, the FDA approved Pluvicto for use in patients with PSMA-positive metastatic castration-resistant prostate cancer who had received an androgen-receptor pathway inhibitor, and the PSMAfore trial saw a 59% reduction in the risk of radiographic progression or death from the control treatment, further bolstering the case for earlier molecularly guided radioligand treatment and supporting the growth of the theranostics market.
Targeted Radiopharmaceutical Market- Geographical Insights
North America is the leading radiopharmaceuticals market due to the strong network of pharmaceutical companies, biotech developers, academic nuclear-medicine centers, national isotope programs, and specialized manufacturing facilities. The radiopharmaceuticals market is highly dependent on the stable supply of short-lived isotopes, offers limited scope for delays, disruptions, and inventory management errors. Policymakers and pharmaceutical companies throughout the region are prioritizing the development of domestic isotope production capabilities and radioligand manufacturing to ensure an uninterrupted supply of medical isotopes. As of 2025, there are 40000 Mo-99 diagnostic doses produced daily in the US, which underlines the level of nuclear medicine adoption in the region. North America is therefore strongly positioned to benefit from the worldwide in nuclear medicine while also being the driving force behind the development of novel therapeutics.
Europe's targeted radiopharmaceutical landscape is supported by the existing nuclear-medicine infrastructure, pharma expertise, research facilities, and regulations. The region also lacks centralized control over radiopharmaceutical production and distribution, meaning the supply chain is of utmost importance. Moreover, time constraints for isotope use require efficient distribution networks. For example, in April 2025, the European Medicines Agency and Heads of Medicines Agencies released recommendations concerning the radiopharmaceutical supply situation in the EU. This shows that the region has the best conditions to manage and respond to such crises because of the harmonization of regulations, high pharma production capabilities, and proactive measures at multiple levels.
Competition in targeted radiopharmaceuticals market is now focusing on broader areas from target discovery, access to radionuclides, radiochemistry, manufacturing, and clinical development to distribution. Thus, Novartis has developed a comprehensive radioligand platform, while competitors, including Bayer, Lantheus, Curium, and new biotech companies, are positioning themselves to provide diverse products and technologies in therapeutics, diagnostics, manufacturing, and specific areas of radiochemistry. Moreover, the overall capacity of production is critical, as radiopharmaceutical requires a stable and reliable supply chain that produces medicines with a short shelf life. Therefore, Novartis opened its third U.S. radioligand manufacturing facility in the Los Angeles area in November 2025. Hence, the ability to deliver complex radioligands to the clinic reliably allows Novartis to differentiate itself from competitors and provide a consistent supply of medicinal products for clinical partners and patients worldwide.
March 2025, Novartis: The U.S. FDA expanded the indication of Pluvicto for patients with PSMA-positive metastatic castration-resistant prostate cancer who had received androgen-receptor pathway inhibitor therapy and were treatment-naive in the second-line setting. The new indication moved radioligand therapy to an earlier treatment paradigm and extended the indication to a broader patient population.
In November 2025, Novartis opened a new 10,000-square-foot radioligand manufacturing facility in Carlsbad, California. This new U.S. radioligand production site is the company's third in the U.S. The new facility will help meet the needs of manufacturing these complex therapies while supporting the time-sensitive nature of radiolabeled compounds